23andMe Holding Co. (ME)
USD 3.14
(-3.09%)
USD 3.14
(-3.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -291.87 Million USD | -1.52% |
| 2022 | -291.94 Million USD | -10.16% |
| 2021 | -228 Million USD | -58.23% |
| 2020 | -164.95 Million USD | -13.15% |
| 2019 | -191.5 Million USD | 18.51% |
| 2018 | -173.63 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -66.16 Million USD | 67.39% |
| 2023 Q4 | -52.98 Million USD | -141.82% |
| 2023 Q2 | -65.71 Million USD | 29.13% |
| 2023 FY | - USD | -1.52% |
| 2023 Q3 | 126.7 Million USD | 292.82% |
| 2023 Q1 | -92.71 Million USD | -52.22% |
| 2022 Q4 | -60.9 Million USD | 37.27% |
| 2022 Q3 | -97.1 Million USD | -65.62% |
| 2022 Q2 | -58.62 Million USD | 26.88% |
| 2022 Q1 | -80.18 Million USD | -15.45% |
| 2022 FY | - USD | -10.16% |
| 2021 Q3 | -92.81 Million USD | -29.99% |
| 2021 FY | - USD | -58.23% |
| 2021 Q4 | -69.45 Million USD | 25.17% |
| 2021 Q2 | -71.4 Million USD | -93.45% |
| 2021 Q1 | -36.91 Million USD | 40.81% |
| 2020 Q4 | -62.36 Million USD | -54.71% |
| 2020 FY | - USD | -13.15% |
| 2020 Q3 | -40.31 Million USD | -29.67% |
| 2020 Q2 | -31.08 Million USD | 0.33% |
| 2020 Q1 | -31.19 Million USD | 0.0% |
| 2019 FY | - USD | 18.51% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | -36.643% |
| Prenetics Global Limited | -47.89 Million USD | -509.39% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -17201.363% |
| CareDx, Inc | -89.65 Million USD | -225.545% |
| Exact Sciences Corporation | 41.87 Million USD | 796.996% |
| Exagen Inc. | -19.15 Million USD | -1423.907% |
| Inotiv, Inc. | -26.5 Million USD | -1001.162% |
| Guardant Health, Inc. | -433.3 Million USD | 32.64% |
| Biodesix, Inc. | -37.1 Million USD | -686.659% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -11644.672% |
| Precipio, Inc. | -4.31 Million USD | -6659.472% |
| iSpecimen Inc. | -9.1 Million USD | -3106.096% |
| Natera, Inc. | -383.27 Million USD | 23.848% |
| Aspira Women's Health Inc. | -16.49 Million USD | -1669.899% |
| Standard BioTools Inc. | -54.45 Million USD | -435.972% |
| Castle Biosciences, Inc. | -45.02 Million USD | -548.263% |
| Personalis, Inc. | -96.8 Million USD | -201.501% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | -148.266% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -2943.194% |
| OpGen, Inc. | -29.51 Million USD | -889.035% |
| T2 Biosystems, Inc. | -43.87 Million USD | -565.24% |
| Myriad Genetics, Inc. | -67.8 Million USD | -330.493% |
| ICON Public Limited Company | 1.63 Billion USD | 117.888% |
| NeoGenomics, Inc. | -17.6 Million USD | -1557.716% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -17201.363% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 123.97% |
| RadNet, Inc. | 292.78 Million USD | 199.689% |
| MDxHealth SA | -30.46 Million USD | -857.969% |
| Psychemedics Corporation | -251 Thousand USD | -116184.462% |
| Illumina, Inc. | -608 Million USD | 51.994% |
| Check-Cap Ltd. | -17.64 Million USD | -1553.771% |
| Twist Bioscience Corporation | -176.7 Million USD | -65.176% |
| DarioHealth Corp. | -53.49 Million USD | -445.62% |
| Fulgent Genetics, Inc. | -46.55 Million USD | -526.985% |
| Sera Prognostics, Inc. | -35.28 Million USD | -727.143% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -2882.931% |
| OPKO Health, Inc. | -65.51 Million USD | -345.5% |
| Medpace Holdings, Inc. | 363.15 Million USD | 180.372% |
| Neogen Corporation | 182.59 Million USD | 259.846% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -3212.719% |
| Prenetics Global Limited | -47.89 Million USD | -509.39% |
| Mainz Biomed B.V. | -25.01 Million USD | -1066.973% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -3725.696% |
| Trinity Biotech plc | -24.09 Million USD | -1111.196% |
| Neuronetics, Inc. | -22.75 Million USD | -1182.455% |
| Sotera Health Company | 514.14 Million USD | 156.769% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -3725.696% |